The REALYSA study aims to improve knowledge about lymphomas and the lives of patients with lymphomas. Thanks to the large number of patients who participate, it allows sub-studies to be conducted simultaneously on specific research questions. One of his sub-studies is in patients with Burkitt’s lymphoma.
Why is this study being implemented?
Burkitt’s lymphomas represent less than 5% of non-Hodgkin lymphomas in adults. There are very few clinical studies on these extremely rare lymphomas. The last clinical study dates back to 2016 and demonstrated an improvement in management with the addition of immunotherapy (Rituximab) to chemotherapy. New recommendations on diagnostic and therapeutic management were updated in February 2025. There is no very precise information on the treatments that are currently offered to patients in “real life”. The REALYSA study will make it possible to obtain this information.
What are the objectives of the study?
The study aims to describe who patients with Burkitt’s lymphoma are. Demographic data, as well as their state of health and the evolution of it, will be analyzed.
The study also aims to find out what treatments these patients received and how effectively.
This so-called “real-life” data (as opposed to clinical trials) will be useful to better understand how patients are being cared for and what improvements should be considered. They will thus make it possible to improve future therapeutic protocols.
How will the study be carried out?
The study will be based on the analysis of data from the medical records of patients participating in REALYSA.
This study is carried out in collaboration with Dr. Emmanuelle Ferrant (Hospices Civils de Lyon). Researchers involved in this study will have access to data on patients participating in the REALYSA study. No link can be made between the data contained in the reports and the patients participating in REALYSA.
The study will begin in March 2026.
ATTENTION PATIENTS PARTICIPATING IN REALYSA
What does this study mean for you?
This study is only in patients participating in REALYSA who have been, diagnosed with Burkitt’s lymphoma.
If you are in this situation and you agree to have your data used for this study, it has no direct implications for you.
In particular, you will not have to answer any additional questionnaire compared to what is already planned as part of your participation in REALYSA.
What should you do about this study?
There are two options:
- You are not opposed to the use of your data in the context of the study:
– In this case, you don’t have to do anything
- You wish to object to the use of your data in the context of the study:
– In this case, you must inform the doctor who suggested that you participate in the REALYSA study. You can also notify your decision by writing an email to the following address: dpo@lysarc.org.
You will find detailed information on your rights to object to the use of your data on page 12 of the information notice that was given to you when you agreed to participate in REALYSA.